bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2025-70-1-128-137bloodjour-613Research ArticleКАК Я УСТАНАВЛИВАЮ ДИАГНОЗ И КАК Я ЛЕЧУHOW DO I GET A DIAGNOSIS AND HOW I TREATКак я лечу тромботическую тромбоцитопеническую пурпуруHow I treat thrombotic thrombocytopenic purpurahttps://orcid.org/0000-0001-8818-8949ГалстянГ. М.GalstyanG. M.

Галстян Геннадий Мартинович, доктор медицинских наук, заведующий отделением реанимации и интенсивной терапии

125167, г. Москва

Gennadiy M. Galstyan, Dr. Sci. (Med.), Head of the Resuscitation and Intensive Care Department

125167, Moscow

gengalst@gmail.comhttps://orcid.org/0000-0002-8141-9422КлебановаЕ. Е.KlebanovaE. E.

Клебанова Елизавета Евгеньевна, анестезиолог-реаниматолог отделения реанимации и интенсивной терапии

125167, г. Москва

Elizaveta E. Klebanova, Physician of the Resuscitation and Intensive Care Department

125167, Moscow

klebanova.liza@yandex.ruhttps://orcid.org/0000-0003-1492-1735МамлееваС. Ю.MamleevaS. Yu.

Мамлеева Светлана Юрьевна, заведующая экспресс-лабораторией отделения реанимации и интенсивной терапии

125167, г. Москва

Svetlana Yu. Mamleeva, Head of the Express-Laboratory, of the Resuscitation and Intensive Care Department

125167, Moscow

maml.s-yur@yandex.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202513032025701128137Copyright © Галстян Г.М., Клебанова Е.Е., Мамлеева С.Ю., 20252025Галстян Г.М., Клебанова Е.Е., Мамлеева С.Ю.Galstyan G.M., Klebanova E.E., Mamleeva S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/613Введение

Введение. Тромботическая тромбоцитопеническая пурпура (ТТП) — редкое заболевание, проявляющееся неиммунной тромбоцитопенией, микроангиопатической гемолитической анемией и нарушением функций органов и систем.

Цель настоящего сообщения — на примере клинического наблюдения представить тактику диагностики и лечения приобретенной ТТП.

Основные сведения

Основные сведения. Представлено клиническое наблюдение больного 32 лет, у которого ТТП манифестировала анемией, тромбоцитопенией, ишемическим инсультом. Больной получил успешное лечение плазмообменом, преднизолоном, каплацизумабом, ритуксимабом. Разбираются схема диагностики, тактика назначения и отмены тех или иных препаратов.

Introduction

Introduction. Thrombotic thrombocytopenic purpura (TTP) is a rare disease manifested by non-immune thrombocytopenia, microangiopathic hemolytic anemia and organ and system dysfunction.

Aim

Aim: to present the scheme of treatment of a patient with TTP.

Main findings

Main findings. The case report of a 32-years-old patient, in whom TTP manifested with anemia, thrombocytopenia, and ischemic stroke, is presented. The patient was successfully treated with plasma exchange, prednisolone, caplacizumab, rituximab. Diagnostic errors, logic of prescription and cancellation of these or those drugs are discussed.

тромботическая тромбоцитопеническая пурпураADAMTS13каплацизумабритуксимабглюкокортикостероидыthrombotic thrombocytopenic purpuraADAMTS13caplacizumabrituximabglucocorticosteroidsработа не имела спонсорской поддержки.the study had no sponsorship.ReferencesScully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. DOI: 10.1111/jth.13571.Scully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. DOI: 10.1111/jth.13571.Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of PregnancyOnset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open. 2018;02(01):e8–15. DOI: 10.1055/s-0037-1615252.Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of PregnancyOnset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open. 2018;02(01):e8–15. DOI: 10.1055/s-0037-1615252.Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45. DOI: 10.1016/S2352-3026(16)30018-7.Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45. DOI: 10.1016/S2352-3026(16)30018-7.Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(3):139–59.Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(3):139–59.Yamada Y., Ohbe H., Yasunaga H., et al. Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A nationwide Inpatient Database Analysis. Blood. 2019;134(Suppl 1):2374. DOI: 10.1182/blood-2019-125170.Yamada Y., Ohbe H., Yasunaga H., et al. Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A nationwide Inpatient Database Analysis. Blood. 2019;134(Suppl 1):2374. DOI: 10.1182/blood-2019-125170.Галстян Г.М., Клебанова Е.Е., Мамлеева С.Ю. и др. Неврологические нарушения у пациентов с тромботической тромбоцитопенической пурпурой. Клиническая медицина. 2023;101(1):41–9. DOI: 10.30629/0023-2149-2023-101-1-41-49.Galstyan G.M., Klebanova E.E., Mamleeva S.Yu., et al. Neurological disorders in patients with thrombotic thrombocytopenic purpura. Klinicheskaya meditsina. 2023;101(1):41–9 (In Russian). DOI: 10.30629/0023-2149-2023-101-1-41-49.Zhang X.-H., Liang H.-M. Systematic review with network meta-analysis. Diagnostic values of ultrasonography, computed tomography, and magnetic reso nance imaging in patients with ischemic stroke. Medicine. 2019;98(30):e16360. DOI: 10.1097/md.0000000000016360.Zhang X.-H., Liang H.-M. Systematic review with network meta-analysis. Diagnostic values of ultrasonography, computed tomography, and magnetic resonance imaging in patients with ischemic stroke. Medicine. 2019;98(30):e16360. DOI: 10.1097/md.0000000000016360.Matsumoto M., Fujimura Y., Wada H., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. International journal of hematology. 2017;106(1):3–15. DOI: 10.1007/S12185-017-2264-7.Matsumoto M., Fujimura Y., Wada H., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. International journal of hematology. 2017;106(1):3–15. DOI: 10.1007/S12185-017-2264-7.Галстян Г.М., Клебанова Е.Е., Мамлеева С.Ю. и др. Иммунная тромбоцитопеническая пурпура и тромботическая тромбоцитопеническая пурпура — сложности и ошибки диагностики. Гематология и трансфузилогия. 2023;68(3):317–34. DOI: 10.35754/0234-5730-2023-68-3-317-334.Galstyan G.M., Klebanova E.E., Mamleeva S.Yu., et al. Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura — diagnostic difficulties and errors. Gematologiya i transfuziologiya. 2023;68(3):317–334 (In Russian). DOI: 10.35754/0234-5730-2023-68-3-317-334.Alwan F., Vendramin C., Vanhoorelbeke K., et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–71. DOI: 10.1182/BLOOD-2016-12-758656.Alwan F., Vendramin C., Vanhoorelbeke K., et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–71. DOI: 10.1182/BLOOD-2016-12-758656.Benhamou Y., Boelle P.Y., Baudin B., et al. Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the french thrombotic microangiopathies reference center. J Thromb Haemost. 2015;13(2):293–302. DOI: 10.1111/jth.12790.Benhamou Y., Boelle P.Y., Baudin B., et al. Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the French thrombotic microangiopathies reference center. J Thromb Haemost. 2015;13(2):293–302. DOI: 10.1111/jth.12790.Wahla A.S., Ruiz J., Noureddine N., et al. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. European journal of haematology. 2008;81(4):311–6. DOI: 10.1111/J.1600-0609.2008.01112.X.Wahla A.S., Ruiz J., Noureddine N., et al. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. European journal of haematology. 2008;81(4):311–6. DOI: 10.1111/J.1600-0609.2008.01112.X.Moiseev I.S., Rzepecki P., Bogardt J., et al. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019;54(7):1022-1028. DOI: 10.1038/s41409-018-0374-3.Moiseev I.S., Rzepecki P., Bogardt J., et al. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation. 2018; DOI: 10.1038/s41409-018-0374-3.Yu K., Yan M. A Case of Thrombotic Thrombocytopenic Purpura without Pathognomonic Schistocytes.pdf. Clin Pract. 2021;11:223–7. DOI: 10.3390/clinpract11020033.Yu K., Yan M. A Case of Thrombotic Thrombocytopenic Purpura without Pathognomonic Schistocytes.pdf. Clin Pract. 2021;11:223–7. DOI: 10.3390/clinpract11020033.Francis K.K., Kalyanam N., Terrell D.R., et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12(1):11–9. DOI: 10.1634/theoncologist.12-1-11.Francis K.K., Kalyanam N., Terrell D.R., et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12(1):11–9. DOI: 10.1634/theoncologist.12-1-11.Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. American journal of hematology. 2015;90(6):E127–9. DOI: 10.1002/AJH.23997.Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. American journal of hematology. 2015;90(6):E127–9. DOI: 10.1002/AJH.23997.Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI: 10.4161/org.7.1.14027.Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI: 10.4161/org.7.1.14027.Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI: 10.1056/NEJM199108083250604.Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI: 10.1056/NEJM199108083250604.Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11(3):220–6. DOI: 10.1007/s12254-018-0429-6.Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11(3):220–6. DOI: 10.1007/s12254-018-0429-6.Bell W.R., Ness P.M., Kickler T.S., et al. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI: 10.1056/NEJM199108083250605.Bell W.R., Ness P.M., Kickler T.S., et al. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI: 10.1056/NEJM199108083250605.Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high‐dose corticosteroid. Am J Hematol. 1992;41(1):69. DOI: 10.1002/ajh.2830410119.Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroid. Am J Hematol. 1992;41(1):69. DOI: 10.1002/ajh.2830410119.Scully M., Нunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35. DOI: 10.1111/j.1365-2141.2012.09167.x.Scully M., Нunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35. DOI: 10.1111/j.1365-2141.2012.09167.x.Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytope nic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI: 10.1111/j.1538-7836.2006.01879.x.Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI: 10.1111/j.1538-7836.2006.01879.x.Azoulay E., Bauer P.R., Mariotte E., et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518–39. DOI: 10.1007/s00134-019-05736-5.Azoulay E., Bauer P.R., Mariotte E., et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518–39. DOI: 10.1007/s00134-019-05736-5.Scully M., Cataland S.R., Peyvandi F., et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335– 46. DOI: 10.1056/nejmoa1806311.Scully M., Cataland S.R., Peyvandi F., et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335– 46. DOI: 10.1056/nejmoa1806311.Coppo P., Bubenheim M., Azoulay E., et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–42. DOI: 10.1182/blood.2020008021.Coppo P., Bubenheim M., Azoulay E., et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–42. DOI: 10.1182/blood.2020008021.Chen J., Reheman A., Gushiken F.C., et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clini Invest. 2011;121(2):593–603. DOI: 10.1172/JCI41062.Chen J., Reheman A., Gushiken F.C., et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clini Invest. 2011;121(2):593–603. DOI: 10.1172/JCI41062.Li G.W., Rambally S., Kamboj J., et al. Treatment of refractory thrombotic thrombocytopenic purpura with N -acetylcysteine: a case report. Transfusion. 2014;54(5):1221–4. DOI: 10.1111/trf.12440.Li G.W., Rambally S., Kamboj J., et al. Treatment of refractory thrombotic thrombocytopenic purpura with N -acetylcysteine: a case report. Transfusion. 2014;54(5):1221–4. DOI: 10.1111/trf.12440.Rottenstreich A., Hochberg-Klein S., Rund D., et al. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016;41(4):678–83. DOI: 10.1007/s11239-015-1259-6.Rottenstreich A., Hochberg-Klein S., Rund D., et al. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016;41(4):678–83. DOI: 10.1007/s11239-015-1259-6.Coppo P., Cuker A., George J.N. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3(1):26–37. DOI: 10.1002/RTH2.12160.Coppo P., Cuker A., George J.N. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3(1):26–37. DOI: 10.1002/RTH2.12160.Mazepa M., Masias C., Chaturvedi S. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood. 2019;134(5):415–20.Mazepa M., Masias C., Chaturvedi S. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood. 2019;134(5):415–20.Volker L.A.., Kaufeld J., Miesbach W., et al. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv. 2020;4(13):3093–101. DOI: 10.1182/bloodadvances.2020001987.Volker L.A.., Kaufeld J., Miesbach W., et al. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv. 2020;4(13):3093–101. DOI: 10.1182/bloodadvances.2020001987.Cuker A., Cataland S.R., Coppo P., et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855– 61. DOI: 10.1182/blood.2020009150.Cuker A., Cataland S.R., Coppo P., et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855– 61. DOI: 10.1182/blood.2020009150.Upreti H., Kasmani J., Dane K., et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037– 45. DOI: 10.1182/blood.2019001056.Upreti H., Kasmani J., Dane K., et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037– 45. DOI: 10.1182/blood.2019001056.George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/ Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI: 10.1002/jca.20091.George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI: 10.1002/jca.20091.Chen H., Fu A., Wang J., et al. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI: 10.1177/0300060517695646.Chen H., Fu A., Wang J., et al. Rituximab as fi rst-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI: 10.1177/0300060517695646.McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI: 10.1111/j.1538-7836.2010.03818.x.McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI: 10.1111/j.1538-7836.2010.03818.x.Sadler J.E.E. Pathophysiology of Thrombotic Thrombocytopenic Purpura. Blood. 2017;130(10):1181–8. DOI: 10.1182/blood-2017-04-636431.Sadler J.E.E. Pathophysiology of Thrombotic Thrombocytopenic Purpura. Blood. 2017;130(10):1181–8. DOI: 10.1182/blood-2017-04-636431.Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI: 10.1182/bloodadvances.2017008268.Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI: 10.1182/bloodadvances.2017008268.Galstyan G.M., Klebanova E., Mamleeva S., et al. Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura. Semin Thromb Hemost. 2024;18–21. DOI: 10.1055/s-0044-1791780.Galstyan G.M., Klebanova E., Mamleeva S., et al. Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura. Semin Thromb Hemost. 2024;18– 21. DOI: 10.1055/s-0044-1791780.

The authors declare that there are no conflicts of interest present.